Back
75· Active
Health & Science2d 5h ago
The FDA has granted clearance for the first human clinical trial of a CRISPR-based gene editing therapy targeting a specific form of hereditary metabolic deficiency.
Silver Spring, Maryland, USA
Who
U.S. Food and Drug Administration (FDA) and Intellia Therapeutics
What
The FDA has granted clearance for the first human clinical trial of a CRISPR-based gene editing therapy targeting a specific form of hereditary metabolic deficiency.
When
Sun, 07 Jun 2026 04:50:05 GMT · 2d 5h ago
Where
Silver Spring, Maryland, USA · 39.0350°N, 76.9950°W
Why
The decision follows promising preclinical safety data suggesting the therapy can permanently correct genetic defects in liver cells.
The Frontline Impact
How this affects you
This authorization paves the way for permanent one-time cures for chronic conditions, potentially reducing the lifetime medical costs and treatment-dependency for thousands of patients.
Story chain
1 event in this threadNo related history yet — this is the origin event.
Verified Sources & Citations
- HIGHSTAT Newshttps://www.statnews.com/
- HIGHReutershttps://www.reuters.com/business/healthcare-pharmaceuticals/
Credibility ratings reflect the AI ingestion pipeline's assessment of source provenance.